| Ticker: | TRVI |
| Current Price: | $13.65 |
| % Daily Change: | 0.22% |
| Volume (1,000s): | 1,099.90 |
| Average Volume (1,000s): | 2,084.79 |
| Market Cap (M): | $1,945.93 |
| 1/2/2024 Price: | $1.30 |
| Change Since Inception: | 950.00% |
Trevi Therapeutics, Inc.
195 Church Street
16th Floor
New Haven, CT 06510
United States
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio™ (nalbuphine ER). Haduvio’s unique centrally and peripherally active mechanism of action (MOA) has the potential to rebalance the kappa and mu receptors which may play a significant role in chronic cough. Haduvio demonstrated a 75% reduction in daytime cough frequency for idiopathic pulmonary fibrosis (IPF) patients in its Phase 2 Cough And NALbuphine trial. With this positive data, Trevi is focusing future clinical development on chronic cough conditions, including IPF, interstitial lung diseases, and refractory chronic cough.